Search Results
Showing Results for gefapixant
COUGH 1 and COUGH 2, were randomized, double-blind, placebo-controlled phase 3 trials, that investigated gefapixant for the treatment of refractory or unexplained chronic cough. It was a pleasure to speak with Dr. Imran Satia (McMaster University, Hamilton, ON, Canada) around his analysis of ...
With limited options in the treatment paradigm for refractory or unexplained chronic cough, P2X3 receptor antagonists have shown great promise in clinical trials. We were delighted to speak to Dr. Imran Satia (McMaster University, Hamilton, ON, Canada) to discuss ...
Chronic cough is a cough that lasts 8 weeks or longer and is not due to serious underlying conditions. It is a common problem in primary care, accounting for up to 40% of referrals to pulmonologists.1 Common causes include rhinosinusitis, cough-variant asthma, ...
Gefapixant is a P2X3 antagonist that was recently studied in two phase 3 randomized controlled trials, COUGH-1 and COUGH-2, and is currently under regulatory review in Europe. In this interview, we were delighted to speak with Elena Kum (McMaster University, ...
Chronic cough, defined as a cough lasting over 8 weeks, has an estimated global prevalence of 10% and has significant detrimental physical, social and psychological consequences on individuals.1,2Â Chronic cough is a complex heterogeneous disease, in which many causative factors need to ...
Welcome to the latest edition of touchREVIEWS in Respiratory & Pulmonary Diseases, which aims to provide insightful and topical articles relevant to the everyday practice of busy physicians. Our popular expert interviews provide a snapshot of hot topics in medicine. ...
With the advent of newer drugs targeting the biochemical pathways that lead to cough, it is increasingly important to understand the definition, pathogenesis and management of this symptom. Several specialist bodies also recognize the need for guidance in this area, ...
touchRESPIRATORY caught up with Dr. Michael S. Blaiss (Medical College of Georgia, Augusta University, Augusta, GA, USA) to discuss his analysis of phase 3 trials of gefapixant in chronic cough. The abstract 'Comparisons Of Baseline Characteristics And Treatment Efficacy In Individuals ...
We were delighted to talk with Dr. Michael S. Blaiss (Medical College of Georgia, Augusta University, Augusta, GA, USA) to discuss chronic cough and the latest advances to look out for in 2022. The abstract 'Comparisons Of Baseline Characteristics And Treatment ...
It was a pleasure to meet with Professor Peter Dicpinigaitis (Albert Einstein College of Medicine and Montefiore Cough Center, NY, USA) to discuss the findings from the COUGH-1 and COUGH-2 studies, investigating gefapixant for the treatment of patients with chronic ...
We were delighted to talk with Professor Jacky Smith (School of Biological Sciences, The University of Manchester, Manchester, UK) around cough frequency with gefapixant in patients with chronic cough. The abstract ‘Objective Cough Frequency with Gefapixant in Chronic Cough: A ...
TouchRESPIRATORY got the opportunity to catch up with Alyn Morice (University of Hull, Castle Hill Hospital, Yorkshire, UK) around the unmet needs and treatment of patients with chronic cough (Clinical Trial Identifier: NCT03449134 & NCT03449147). The abstract ‘Cough Triggers and ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
